Phase 4 N=15 Antithrombotic Effects of Ticagrelor Versus Clopidogrel
Acute Coronary Syndrome
Primary: Platelet-thrombus Formation in an ex Vivo Model of Thrombosis — 56.3; 35.2 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=200 Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
Phase 4 N=1,829 How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
Acute ST Elevation Myocardial Infarction
Primary: Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion…
Phase 4 N=114 Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
CVD
Primary: Number of Participants With Occlusion and Restenosis at One Year — 58; 56 participants
Phase 2 N=425 Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass
Cardiac Surgery · Cardiopulmonary Bypass
Primary: Percentage of Subjects With Any Component of a Major Morbidity Composite — 68; 58 Participants
Phase 2 N=57 Thromboxane Receptor Antagonist to Improve Endothelial Function
Cardiovascular Diseases · Vascular Dilation
Primary: Change in Reactive Hyperemia Index (RHI) — -0.01; 0.21 percentage index change
Phase 2 N=40 Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
Phase 4 N=49 APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Myocardial Infarction
Primary: 6-month Reocclusion — 1; 4 participants
Phase 4 N=60 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
Aortic Stenosis · Inflammation · Thrombosis
Primary: Platelet Reactivity — 275.5; 251; 234; 128.5 Platelet Reactivity Units
N/A N=70 Transcranial Doppler (TCD) Assessment During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement
Aortic Valve Disease
Primary: Differences in the Rate of Doppler-detected Cerebral Micro Emboli Between the Two Prophylactic Treatments of Thrombosis — 1.1; 0.7; 1.0; 0.7 MES counts
N/A N=140 Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Hemorrhage, Surgical · Blood Loss, Surgical · Blood Loss, Postoperative
Primary: Incidence of Perioperative (Periop) Bleeding, Primary Effectiveness Composite Endpoint, Modified Intent to Treat (mITT) Population — 2103; 2244 number of wins — p=0.748
Phase 4 N=516 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
Thrombosis
Primary: Major Bleeding — 0 participants
N/A N=341 Anticoagulation With Enhanced Gastrointestinal Safety
Upper Gastrointestinal Bleeding · Peptic Ulcer Hemorrhage · Anticoagulant-induced Bleeding
Primary: ITT Analysis - Percent of Patients Reporting Medication Optimization — 30; 2; 29; 65 Participants — p=<0.001
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
N/A N=977 Randomized On-X Anticoagulation Trial
Heart Valve Disease
Primary: Thromboembolism — 4.86; 0.29; 2.43; 1.74 %/patient years
Phase 4 N=103 Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
Traumatic Injury · Venous Thromboembolism
Primary: Initial AT-III Activity -- Control Group vs. Intervention Group Prior to Randomization — 87; 82 Percent AT-III activity (%) — p=0.092
Phase 2 N=55 Antiplatelet Therapy in HIV
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
Phase 2 N=123 A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
Coronary Artery Disease
Primary: Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose — 93.15; 31.05 Percentage
Phase 4 N=100 Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Coronary Artery Disease
Primary: Thrombin Generation Test: Baseline — 1810; 1682 nM*minutes
Phase 3 N=12,424 PREVENTion of Clot in Orthopaedic Trauma
Blood Clot · Trauma
Primary: Number of Participants With All-cause Mortality — 45; 47 Participants
N/A N=300 Simplified Anti-Thrombotic Therapy for FFR
Coronary Artery Disease
Primary: Thrombotic Complications — 0; 0; 0 Number of Patients — p=1
Phase 4 N=60 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL
N/A N=35 The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial
Left Atrial Appendage Closure · WATCHMAN Device Implantation
Primary: Comparison of Thrombin Induced Platelet-fibrin Clot Strength (TIP-FCS) Between Patients With and Without Device Related Thrombosis (DRT) Assessed at 1-year of Watchman…
N/A N=1,175 Toronto Thromboprophylaxis Patient Safety Initiative
Venous Thromboembolism
Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients
Phase 4 N=130 Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
Myocardial Infarction
Primary: Maximal Platelet Aggregation — 52; 64; 74 percent aggregation — p=0.011
Phase 3 N=18 Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
N/A N=411 Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 3 N=1,217 COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
Covid19
Primary: Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial…
Phase 4 N=250 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded